Latitude Advisors’s GSK GSK Stock Holding History

Latitude Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-5,098	Closed	-$219K	–	186
2024 Q1	$219K	Buy	+5,098	New	+$210K	0.14%	161
2023 Q4	–	Sell	-5,608	Closed	-$203K	–	179
2023 Q3	$203K	Buy	+5,608	New	+$199K	0.15%	156

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Latitude Advisors's GSK Position: Q2 2024 in Review

Latitude Advisors sold out of GSK (GSK) in Q2 2024, closing a stake of 5,098 shares — an estimated $219K sold.

Latitude Advisors first reported a position in GSK in Q3 2023 and held it in 2 quarters. The position peaked at $219K in Q1 2024. 884 funds tracked by Wall St. Rank hold GSK as of Q2 2024.

Latitude Advisors reported no remaining GSK position as of Q2 2024 after selling out during the quarter.
Latitude Advisors sold 5,098 GSK shares in Q2 2024, an estimated $219K.
Latitude Advisors first reported a position in GSK in Q3 2023 and held it in 2 quarters.
Latitude Advisors's GSK position peaked at $219K in Q1 2024.
884 funds tracked by Wall St. Rank held GSK as of Q2 2024.

Based on Latitude Advisors's 13F filing for Q2 2024, filed 26 Jul 2024.